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IntroductIon
Systemic sclerosis (SSc) is an autoimmune disease of
unknown etiology, characterized by skin fibrosis, vas-
cular walls and some internal organs, such as the di-
gestive tract, lung, heart or kidney. This fibrosis appears
as a result of a process not fully understood, which in-
cludes microvascular damage, immunological disorder
and hyperproduction of collagen and extracellular ma-
trix proteins. Clinically, it is very heterogeneous, so it
is usually divided into two large groups: SSc with dif-
fuse cutaneous involvement (dcSSc), with extensive
dermal hardening and frequent organic involvement
and SSc limited cutaneous (lcSSc), with more limited
hardening and less organic involvement1. 
Calcinosis cutis, is a characteristic clinical manifes-
tation of SSc, and the reason why calcium salts (calci-
um phosphate, hydroxyapatite) are deposited in the
skin and subcutaneous tissues remains unclear2. 
Fibroblast growth factor-23 (FGF-23), is a protein
of 251 amino acids synthesized and secreted by bone
cells, mainly the osteocyte3. This full-length protein is
recognized as a biologically active hormone that plays
a key role in the complex network between the bones
and other organs4. FGF-23 has been described to have
detrimental effects on the heart, promoting left ven-
tricular hypertrophy; the liver, leading to production
of inflammatory cytokines; the bones, inhibiting min-
eralization; and the bone marrow, by reducing the pro-
duction of erythropoietin5-8. Included in the group of
hormones known as phosphatonins9, it has been iden-
tified as the main regulatory factor of phosphate
metabolism10. The increase in serum phosphate levels
stimulates production of FGF-23 by bone and vicever-
sa11. Alterations in both FGF-23 and phosphate levels
can lead to the appearance of extraosseous calcifica-
tions12, caused by the dangerous association of hyper-
calcemia and hyperphosphatemia. Given the broad list
of effects associated with the high levels of FGF-23, it
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AbstrAct 
Objective:  Systemic sclerosis (SSc) is a complex dis-
order of unknown etiology. The purpose of this study
was to evaluate fibroblast growth factor-23 (FGF-23)
serum levels in women with SSc compared with healthy
controls and to examine a possible association between
FGF-23 serum levels with the presence of calcinosis in
SSc patients. 
Methods: This cross-sectional study was performed in
San Cecilio Hospital, Granada (Spain) from November
2017 to May 2019. Sixty-two women with SSc and 62
age and sex matched healthy controls were included in
this study. FGF-23 serum concentration was evaluated
by indirect enzyme-linked immunosorbent assay
(ELISA). 
Results: There was no significant difference in FGF-23
levels between SSc patients and healthy controls (78.2
± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the
characteristics of the disease, we found a relationship
between the values of FGF-23 and the presence of cal-
cinosis. The levels of FGF-23 are higher in patients suf-
fering from calcinosis (p= 0.028). 
Conclusion: We observed the presence of higher lev-
els of serum FGF-23 in SSc female patients with calci-
nosis. Therefore, FGF-23 could be a possible thera-
peutic target for future treatments. 
Keywords: Fibroblast growth factor-23; Systemic scle-
rosis; calcinosis.
ÓRGÃO OfICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
260
Role of fibRoblast gRowth factoR-23 in calcinosis in women with ssc
would be reasonable to think of FGF-23 as a clinical
target.
There is a lack of evidence regarding the potential
role of FGF-23 in the pathogenesis of SSc, so we aimed
to evaluate FGF-23 serum levels in women with SSc
compared with healthy controls and to examine a pos-
sible association between FGF-23 serum levels with
the presence of calcinosis in SSc patients. 
MAterIAls And Methods
study subjects
This cross-sectional study was performed in San Ce-
cilio Hospital, Granada (Spain) from November 2017
to May 2019. We prospectively enrolled 62 consecu-
tive female patients affected by SSc ≥ 18 years old at-
tending our Systemic Autoimmune Diseases Unit. In
addition, a control group of 62 healthy women age-
matched, recruited mainly among nonmedical staff of
our hospital that attended their annual medical health
examination and who were invited to participate were
included.  All patients included in this study had nor-
mal serum creatinine (Cr) levels, and met the 2013
American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) criteria for SSc13.
The clinical diagnosis of SSc was per-formed by the
rheumatologists.
We selected only women for the study because the
distribution of FGF-23 concentration differs by sex14.
This can be influenced by different hormones, among
which are estrogens (estradiol)15. To exclude these prob-
lems, we selected female subjects in the current study.
At the clinic visit, participants completed question-
naires about their lifestyle characteristics, medical his-
tory, previous and concomitant treatment, and demo-
graphic data were taken. Informed consent was
obtained for all subjects, and the study was approved
by the Research Ethics Committee of Hospital Clinico
Universitario San Cecilio in Granada, Spain, and con-
ducted in accordance with the guidelines in the Dec-
laration of Helsinki.
lAborAtory MeAsureMents
In all the cases, a fasting blood sample was taken in
the morning, and was stored at -70°C until the assays
were performed.
The sera were tested for creatinine, calcium, phos-
phorus, alkaline phosphatase, 25-Hydroxy vitamin D,
parathyroid hormone, and FGF-23.
Creatinine was determined by Jaffe method
(Siemens Healthcare Diagnostic Inc. NY, USA). Calci-
um and phosphorus were determined colorimetrically
using commercial reagents in an automated chemical
analyzer (Siemmens Healthcare Diagnostic Inc. NY,
USA). Alkaline phosphatase was determined with stan-
dard automated equipment. The 25-Hydroxy vitamin
D and parathyroid hormone were measured by chemi-
luminescent assays (Dia Sorin.Saluggia, Italy). Antinu-
clear antibodies were assessed using ELISA kits pro-
duced by Generic Assay Dahlewitz Germany.
Serum FGF-23 (Elabscience, USA) was measured by
ELISA according to the manufacturer’s recommenda-
tions. All other routine serum biochemistries were mea-
sured at the Department of Clinical Chemistry, San Ce-
cilio Hospital.
stAtIstIcAl AnAlysIs 
The results were analyzed using SPSS (version 21). Con-
tinuous variables were reported as means ± standard de-
viations and median (Q1–Q3) as suitable, while cate-
gorical variables were expressed as frequency and
percentage. Comparisons of data between groups were
made by Mann-Whitney U test and Wilcoxon test where
appropriate. P values of less than 0.05 were considered
statistically significant. Assuming an alpha risk of 0.05%,
with a power of 80% and with a maximum error of 15
units, a minimum sample size of 58 patients was calcu-
lated. The subgroup analyses were pre-speci fied.
results
chArActerIstIcs of the study subjects
The main features of the 62 women with SSc and 62
controls included in this study are shown in Table I.
The mean age (SD) of the patients was 53 ± 10 years.  
The majority were Caucasian (90.5%). The mean di -
sease duration was 8.8 ± 6.9 years. Forty-four (70.9%)
patients had a limited form of the disease and 18
(29.1%) had a diffuse form. Twelve (19%) patients had
calcinosis and all patients had Raynaud Phenomenon. 
The mean age (SD) of the controls was 52 ± 9 years.
Most of them were also Caucasian (98.3%).
The main difference found between the two groups
was the presence of a greater number of smokers in
healthy controls.
lAborAtory results
Laboratory tests of the patients and healthy controls
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included in the present study are shown in Table II. As
expected, laboratory markers of inflammation found
at the time of the study were higher in women with SSc
than in controls. In this regard, the mean CRP in SSc
patients was 0.4 ± 0.4 mg/dl versus 0.2 ± 0.1 mg/dl in
controls (p =0.007). Likewise, the mean ESR in the
group of SSc patients was 21.1 ± 16 mm/1st hour ver-
sus 11.3 ± 10.2 mm/1st hour in controls (p <0.001).
Antinuclear antibodies (ANAs) were detected in 54 pa-
tients (87.1%), anti-centromere antibodies in 34 patients
(54.8%) and anti-Scl-70 antibodies in 6 patients (9.6%). 
There were no significant differences in FGF-23 le -
vels between the patients and controls [78.2 ± 60.5 vs.
80.3 ± 56.3, pg/ml; p=0.662].
tAble I. chArActerIstIcs of woMen wIth systeMIc sclerosIs And heAlthy controls 
SSc HC
mean ± SD mean ± SD p-value
Age, years 53.2 ± 10.1 52.7 ± 9.7 0.71
Height, cm 159.5 ± 5.6 160.9 ± 7.1 0.23
Body weight, kg 66.8 ± 12 67.2 ± 12 0.90
Body mass index, kg/m2 26.3 ± 4.9 25.9 ± 4.3 0.90
Waist circumference 83.5 ± 11 83.1 ± 13.4 0.64
Smoking, n (%) 11 (17.7) 15 (24.2) 0.04
Hypertension, n (%) 8 (12.9) 11 (17.7) 0.87
Diabetes mellitus, n (%) 2 (3.2) 2 (3.2) 0.62
Dyslipidemia, n (%) 21 (33.8) 14 (22.5) 0.17
Disease duration, year 8.8 ± 6.9 - -
lcSSc, n (%) 44 (70.9) - -
dcSSc, n (%) 18 (29.1) - -
Calcinosis, n (%) 12 (19.3) - -
ANAs, n (%) 54 (87.1) - -
Anti-centromere, n (%) 34 (54.8) - -
Anti-Scl70, n (%) 6 (9.6) - -
SD: standard deviation; SSc: systemic sclerosis; HC: healthy control; lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous SSc; 
ANA: antinuclear antibodies.
tAble II. seruM fGf-23 And seruM bIocheMIstrIes of the pAtIents And heAlthy controls
SSc HC
mean ± SD mean ± SD p-value
FGF-23, pg/ml 78.2 ± 60.5 80.3 ± 56.3 0.662
CRP, mg/dl 0.4 ± 0.4 0.2 ± 0.1 0.007
ESR, mm/h 21.1 ± 16 11.3 ± 10.2 0.001
Serum phosphate, mg/dl 3.6 ± 0.5 3.4 ± 0.5 0.04
Serum calcium, mg/dl 9.5 ± 0.3 9.4 ± 0.4 0.05
Alkaline phosphatase, IU/L 104 ± 130.5 72.9 ± 19.5 0.07
25-(OH)D, ng/ml 26 ± 12 23.1 ± 7.3 0.31
Intact PTH, pg/ml 50.7 ± 27.3 54.9 ± 19.6 0.02
Serum creatinine, mg/dl 0.7 ± 0.8 0.7 ± 0.2 0.12 
eGFR, ml/min 93 ± 17.2 97 ± 13.2 0.19
SD: standard deviation; SSc: systemic sclerosis; HC: healthy control; FGF-23: fibroblast growth factor-23; 25-(OH)D: 25-hydroxy vitamin D;
PTH: parathyroid hormone; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; GFR:  estimated glomerular filtration rate
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found also regarding the levels of FGF23 in terms of the
presence of anti-centromere antibody [91.9 ± 74.6 vs.
87.4 ± 91.5, pg/ml; p=0.837], anti-Scl-70 antibody
[74.6 ± 37.2 vs.90.7 ± 84, pg/ml; p=0.745] and ANAs
antibodies [85.7 ± 87 vs. 104.2 ± 63.3, pg/ml;
p=0.480]. No significant differences were found in
serum FGF-23 levels according to the presence of car-
diac [91.7 ± 80 vs. 84.6 ± 73.2, pg/ml; p=0.729] or lung
involvement [94.2 ± 73.3 vs. 87.5 ± 82, pg/ml;
p=0.592].
When patients were subdivided according to the
presence of calcinosis, a significant difference was
obser ved in serum FGF-23 concentration. The levels of
FGF-23 were higher in patients with calcinosis [156.7
± 126.1 vs. 73.3 ± 59.6, pg/ml;  p=0.028] (Figure 1).
correlAtIon between fGf-23 levels And 
AnAlytIcAl pArAMeters
Table III shows the correlation coefficients between
FGF-23 and analytical parameters in SSc patients.
FGF-23 levels did not show correlation with 25-
fGf-23 levels In ssc pAtIents wIth 
dIfferent clInIcAl chArActerIstIcs
In the sub-group analysis, based on diffused and limi -
ted forms of the disease, no significant differences were
found in serum FGF-23 levels [92.2 ± 93.3 vs. 95.4 ±
78.7 pg/ml; p=0.786]. No significant differences were
fIGure 1. Median serum concentration of fibroblast growth factor-23 in Systemic sclerosis patients with calcinosis (n=12) and 
Systemic sclerosis patients without calcinosis (n=50). Wilcoxon test for paired sample. 
tAble III. correlAtIons between fGf-23 And
AnAlytIcAl pArAMeters In ssc pAtIents.
Correlation
coefficient p
Serum phosphate 0.05 0.704
Serum calcium -0.25 0.051
25-(OH)D 0.21 0.106
Intact PTH 0.05 0.728
Alkaline phosphatase -0.14 0.276
FGF-23: fibroblast growth factor-23, SSc: systemic sclerosis, 
25-(OH)D: 25-hydroxy vitamin D, PTH: parathyroid hormone
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(OH)D, iPTH, alkaline phosphatase, total calcium and
phosphate levels.
dIscussIon
In the present study, there was no significant difference
in the FGF-23 levels between SSc female patients and
healthy controls; however, the levels of FGF-23 were
higher in patients suffering from calcinosis.
SSc is a multisystemic disease characterized by vas-
cular, immunological alterations and excessive accu-
mulation of connective tissue components that cause
cutaneous sclerosis and fibrosis of different organs16. 
FGF-23 is an osteocyte-derived hormone that par-
ticipates in vitamin D and phosphate me tabolism.
Changes in the serum levels of FGF-23 are particular-
ly involved in the calcification of peripheral vascula-
ture, the coronary artery and soft tissue17,18.
We have not found a significant difference in FGF-
23 levels between SSc patients and healthy controls in
our study, which was in agreement with the study of
Ahmadi19. Shenavandeh et al.20, in a study in Iran, they
also found no difference between FGF-23 levels of their
patients with SSc and healthy controls, and when they
analyzed the existence of differences in serum levels of
FGF-23 among patients with diffuse or localized dis-
ease, they also found no significant differences. In re-
lation to this data, we have not observed differences in
FGF-23 levels between patients with dcSSc and pa-
tients with lcSSc. 
In SSc, we can find the presence of calcinosis in both
subtypes of the disease (diffuse and limited form)2. We
found significantly elevated FGF-23 serum levels in
SSc patients with calcinosis compared with SSc patients
without calcinosis. FGF-23, specifically binds FGF-re-
ceptor-1-expressing kidney cells, leading to the de-
creased synthesis of active hormone of vitamin D, the
1,25(OH)2D3, by causing repression of the gene for 
α-1 hydroxylase, thereby regulating calcium homeos -
tasis. Ordinarily, FGF-23 also inhibits renal tubular re-
absorption of phosphate by decreasing the gene ex-
pression of Na+-dependent phosphate transporters
(Na/Pi-2a and Na/pi-2c) in the proximal convoluted
tubules. Another function of FGF-23 is to decreases
mRNA transcription of parathyroid hormone, and in-
hibit its secretion21.  Since FGF-23 is a known regula-
tor of all three factors, it is plausible to that FGF-23
could be involved in the mechanism of vascular and
soft tissue calcification.
There are some limitations in our study that should
be considered: this study focused only on SSc female
patients; therefore, the findings of this study cannot be
generalized to men with SSc. This study was a cross-
sectional analysis that reflected the status of a popula-
tion in a particular period, and the small sample size,
with only 12 patients with calcinosis. 
conclusIon
We observed the presence of higher levels of serum
FGF-23 in SSc female patients with calcinosis. There-
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